All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Listed as ongoing, but also has a completion date and reported results | 2014-000667-40 | A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension Az APD811 – egy orálisan alkalm... | 2017-06-22 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2014-003042-27 | An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension Az APD811-003 vizsgálat nyílt kiterjesztett vizsgálata pulmonális artériás hipertóniában szenvedő betege... | 2021-03-29 | bad-data |
Reported results | 2015-001942-28 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative C... | 2018-02-15 | due-trials |
Reported results | 2015-002109-12 | An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis | 2018-11-01 | due-trials |
Reported results | 2016-003797-40 | A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations | 2017-10-02 | due-trials |
Ongoing | 2018-001187-33 | A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients | not-yet-due | |
Ongoing | 2018-001189-40 | A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2018-003985-15 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | 2022-02-16 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2018-003986-33 | A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | 2022-02-01 | bad-data |
Ongoing | 2018-003987-29 | An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2019-002895-14 | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Seve... | 2021-03-23 | bad-data |
Reported results Terminated | 2020-000238-16 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous... | 2022-08-23 | due-trials |
Reported results | 2020-003226-23 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis | 2023-06-30 | due-trials |
Listed as ongoing, but also has a completion date | 2020-003507-34 | A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis | 2024-06-19 | bad-data |
Ongoing | 2020-004775-40 | A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease | not-yet-due | |
Reported results | 2020-006131-10 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects with Heart Failure with R... | 2022-09-10 | due-trials |